A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Registration Number
- NCT02425891
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This multicenter, randomized, double-blind study evaluated the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC). The safety of single-agent nab-paclitaxel has been determined in previous studies of participants with mBC and the safety data to date suggest that atezolizumab can be safely combined with standard chemotherapy agents.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 902
- Metastatic or locally advanced, histologically documented TNBC characterized by absence of human epidermal growth factor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression
- No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC
- Eligible for taxane monotherapy (i.e., absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control)
- A representative formalin-fixed, paraffin-embedded tumor specimen in paraffin blocks, or at least 20 unstained slides with an associated pathology report documenting ER, PR, and HER2 negativity. Participants with fewer than 20 unstained slides available at baseline, and not fewer than 12 unstained slides will be eligible upon discussion with Medical Monitor
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Measurable disease as defined by RECIST v1.1
- Adequate hematologic and end-organ function
- Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases
- Leptomeningeal disease
- Pregnancy or lactation
- History of autoimmune disease
- Prior allogeneic stem cell or solid organ transplantation
- Positive test for human immunodeficiency virus
- Active hepatitis B or hepatitis C
- Receipt of a live, attenuated vaccine within 4 weeks prior to randomization, during treatment, or within 5 months following the last dose of atezolizumab/placebo
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Atezolizumab Plus Nab-Paclitaxel Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity. Atezolizumab Plus Nab-Paclitaxel Nab-Paclitaxel Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity. Placebo Plus Nab-Paclitaxel Placebo Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity. Placebo Plus Nab-Paclitaxel Nab-Paclitaxel Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
- Primary Outcome Measures
Name Time Method Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) in All Randomized Participants Baseline up to approximately 34 months PFS was defined as the time from randomization to the occurrence of disease progression, as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause, whichever occurred first.
OS in Participants With Detectable PD-L1 Baseline until death due to any cause (up to approximately 58 months) OS was defined as the time from the date of randomization to the date of death from any cause.
Overall Survival (OS) in All Randomized Participants Baseline until death due to any cause (up to approximately 58 months) OS was defined as the time from the date of randomization to the date of death from any cause.
PFS According to RECIST v1.1 in Participants With Detectable Programmed Death-Ligand 1 (PD-L1) Baseline up to approximately 34 months PFS was defined as the time from randomization to the occurrence of disease progression, as determined by investigators from tumor assessments per RECIST v1.1, or death from any cause, whichever occurred first.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With an Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 in All Randomized Participants Baseline up to approximately 34 months An objective response was defined for participants with measurable disease at baseline as either a partial response (PR) or a complete response (CR) using RECIST v1.1.
Percentage of Participants With an Objective Response of CR or PR According to RECIST v1.1 in Participants With Detectable PD-L1 Baseline up to approximately 34 months An objective response was defined for participants with measurable disease at baseline as either a partial response (PR) or a complete response (CR) using RECIST v1.1.
Duration of Response (DOR) According to RECIST v1.1 in All Randomized Participants Baseline up to approximately 34 months DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause, whichever occurred first.
DOR Acccording to RECIST v1.1 in Participants With Detectable PD-L1 Baseline up to approximately 34 months DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause, whichever occurred first.
Time to Deterioration (TTD) in Global Health Status/Health Related Quality of Life According to European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) v3.0 in All Randomized Participants Baseline up to approximately 58 months Deterioration in GHS/HRQoL (Items 29, 30 of the EORTC QLQ C30) was defined by the following two criteria: 1. The time from randomization to the first time the participant's GHS/HRQoL scale score showed a \>=10-point decrease from the baseline scale score. A 10-point change was defined as the minimally important difference (MID). 2. The score decrease of \>= 10-points from baseline was held for at least two consecutive cycles, or an initial score decrease of \>= 10-points was followed by death or treatment discontinuation within 3 weeks from the last assessment.
TTD in Global Health Status/Health Related Quality of Life According to EORTC QLQ-C30 v3.0 in Participants With Detectable PD-L1 Baseline up to approximately 58 months Deterioration in GHS/HRQoL (Items 29, 30 of the EORTC QLQ C30) was defined by the following two criteria: 1. The time from randomization to the first time the participants's GHS/HRQoL scale score showed a \>=10-point decrease from the baseline scale score. A 10-point change was defined as the minimally important difference (MID). 2. The score decrease of \>= 10-points from baseline was held for at least two consecutive cycles, or an initial score decrease of \>= 10-points was followed by death or treatment discontinuation within 3 weeks from the last assessment.
Percentage of Participants With at Least One Adverse Event Baseline up to to the data cutoff date: 31 August 2021 (up to approximately 74 months) Percentage of participants with at least one adverse event.
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab Baseline up to approximately 53 months Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab
Maximum Serum Concentration (Cmax) for Atezolizumab Cycle 1 Day 1 (Cycle = 28 days) Maximum serum concentration for atezolizumab.
Minimum Serum Concentration (Cmin) for Atezolizumab Day 27 of Cycle 1, 2, 3, and 7 (Cycle = 28 days) Minimum serum concentration for atezolizumab.
Plasma Concentrations of Total Paclitaxel Pre-dose (Hour 0) on Cycle 1 Day 1, pre-dose (Hour 0), 5-10 minutes before end of nab-paclitaxel infusion, 1 hour after end of nab-paclitaxel infusion (infusion duration = 30 minutes) on Cycle 3 Day 1 (Cycle = 28 days) Plasma Concentrations of Total Paclitaxel
Trial Locations
- Locations (247)
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Treatment and Prevention Institution Volyn Regional Oncology Dispensary
🇺🇦Lutsk, Ukraine
The Methodist Cancer Center
🇺🇸Houston, Texas, United States
University of Texas;M.D. Anderson Cancer Center
🇺🇸Houston, Texas, United States
Royal Marsden Hospital; Dept of Medical Oncology
🇬🇧Sutton, United Kingdom
Sarah Cannon Cancer Center - Tennessee Oncology, Pllc
🇺🇸Nashville, Tennessee, United States
Vanderbilt
🇺🇸Nashville, Tennessee, United States
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Barbara Ann Karmanos Cancer Institute; Oncology
🇺🇸Detroit, Michigan, United States
Kaiser Perm NW - Rheuma
🇺🇸Portland, Oregon, United States
Providence Cancer Center
🇺🇸Portland, Oregon, United States
Univ of Calif, San Francisco; Breast Cancer Center
🇺🇸San Francisco, California, United States
Universitätsklinikum Erlangen; Frauenklinik
🇩🇪Erlangen, Germany
Laura and ISAAC Perlmutter Cancer Center at NYU Langone.
🇺🇸New York, New York, United States
Kaiser Permanente of Northern California
🇺🇸Oakland, California, United States
Highlands Oncology Group
🇺🇸Springdale, Arkansas, United States
Cancer Research Collaboration, Inc.
🇺🇸Santa Ana, California, United States
Stamford Hospital; BCC, MOHR
🇺🇸Stamford, Connecticut, United States
Florida Cancer Specialists - SCRI; Pharmacy
🇺🇸Fort Myers, Florida, United States
MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)
🇺🇸Washington, District of Columbia, United States
The Mount Siani Comprehensive Cancer Center
🇺🇸Miami Beach, Florida, United States
Florida Cancer Research Institute
🇺🇸Plantation, Florida, United States
Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)
🇺🇸Saint Petersburg, Florida, United States
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)
🇺🇸Jacksonville, Florida, United States
Northwest Georgia Oncology Centers PC - Marietta
🇺🇸Marietta, Georgia, United States
Mercy Medical Center
🇺🇸Baltimore, Maryland, United States
Rush University Medical Center - Chicago
🇺🇸Chicago, Illinois, United States
Maryland Oncology Hematology
🇺🇸Rochville, Maryland, United States
West Michigan Cancer Center
🇺🇸Kalamazoo, Michigan, United States
New Hampshire Hematology Oncology
🇺🇸Manchester, New Hampshire, United States
The Valley Hospital
🇺🇸Ridgewood, New Jersey, United States
The Mark H. Zangmeister Ctr; Mid Ohio Onc/Hem Inc.
🇺🇸Columbus, Ohio, United States
Onc/Hem Care Clin Trials LLC
🇺🇸Cincinnati, Ohio, United States
St. Luke's Cancer Care Associates
🇺🇸Bethlehem, Pennsylvania, United States
Greenville Health System (GHS) Cancer Institute
🇺🇸Greenville, South Carolina, United States
West Clinic
🇺🇸Germantown, Tennessee, United States
Texas Oncology- El Paso Cancer Treatment Center Gateway
🇺🇸El Paso, Texas, United States
Inova Medical Group
🇺🇸Fairfax, Virginia, United States
Cancer Care Northwest
🇺🇸Spokane, Washington, United States
Centro de Oncologia e Investigacion Buenos Aires (COIBA)
🇦🇷Buenos Aires, Argentina
Chris O'Brien Lifehouse
🇦🇺Camperdown, New South Wales, Australia
Centro Oncologico Riojano Integral (CORI)
🇦🇷La Rioja, Argentina
Princess Alexandra Hospital; Division of Cancer Services
🇦🇺Woolloongabba, Queensland, Australia
Sunshine Hospital
🇦🇺St Albans, Victoria, Australia
St John of God Hospital; Bendat Cancer Centre
🇦🇺Subiaco, Western Australia, Australia
Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1
🇦🇹Linz, Austria
Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I
🇦🇹Graz, Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I
🇦🇹Wien, Austria
Institut Jules Bordet
🇧🇪Anderlecht, Belgium
A.Ö. Lhk; Ii. Medizinische Abt. Mit Schwerpunkt Gaströnter. & Onkologie
🇦🇹Steyr, Austria
Cliniques Universitaires St-Luc
🇧🇪Bruxelles, Belgium
GHdC Site Notre Dame
🇧🇪Charleroi, Belgium
AZ Groeninge
🇧🇪Kortrijk, Belgium
Sint Augustinus Wilrijk
🇧🇪Wilrijk, Belgium
Centro de Pesquisas Oncologicas - CEPON
🇧🇷Florianopolis, SC, Brazil
Hospital Araujo Jorge; Departamento de Ginecologia E Mama
🇧🇷Goiania, GO, Brazil
Crio - Centro Regional Integrado de Oncologia
🇧🇷Fortaleza, CE, Brazil
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, RS, Brazil
Hospital Sao Lucas - PUCRS
🇧🇷Porto Alegre, RS, Brazil
Clinica de Neoplasias Litoral
🇧🇷Itajai, SC, Brazil
Hospital Perola Byington
🇧🇷Sao Paulo, SP, Brazil
Tom Baker Cancer Centre-Calgary
🇨🇦Calgary, Alberta, Canada
Kingston General Hospital
🇨🇦Kingston, Ontario, Canada
Lakeridge Health Oshawa; Oncology
🇨🇦Oshawa, Ontario, Canada
Sunnybrook Odette Cancer Centre
🇨🇦Toronto, Ontario, Canada
The Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada
Hopital du Saint Sacrement
🇨🇦Quebec City, Quebec, Canada
Jewish General Hospital
🇨🇦Montreal, Quebec, Canada
Sociedad de Investigaciones Medicas Ltda (SIM)
🇨🇱Temuco, Chile
Oncomedica S.A.
🇨🇴Monteria, Colombia
Clinica del Country
🇨🇴Bogota, Colombia
Clinica CIMCA
🇨🇷San José, Costa Rica
ICIMED Instituto de Investigación en Ciencias Médicas
🇨🇷San José, Costa Rica
Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika
🇨🇿Praha 2, Czechia
Fakultni nemocnice v Motole
🇨🇿Praha 5, Czechia
North Estonia Medical Centre Foundation; Oncology Centre
🇪🇪Tallinn, Estonia
Tampere University Hospital; Dept of Oncology
🇫🇮Tampere, Finland
Tartu Uni Hospital; Hematology - Oncology Clinic
🇪🇪Tartu, Estonia
Ico - Paul Papin
🇫🇷Angers, France
Hopital Jean Minjoz
🇫🇷Besancon, France
Institut Sainte Catherine
🇫🇷Avignon, France
HOPITAL MICHALLON - CENTRE HOSPITALIER UNIVERSITAIRE DE GRENOBLE, Service d'oncologie Médicale
🇫🇷Grenoble, France
Clinique Catherine de Sienne
🇫🇷Nantes, France
Centre Oscar Lambret
🇫🇷Lille, France
Institut régional du Cancer Montpellier
🇫🇷Montpellier, France
Hopital La Pitie Salpetriere
🇫🇷Paris, France
Institut De Cancerologie De L'Ouest; Medical Oncology
🇫🇷Saint Herblain, France
Institut Curie
🇫🇷Paris, France
Centre Paul Strauss
🇫🇷Strasbourg, France
St. Johannes Hospital; Abt. für Hämatologie und Onkologie
🇩🇪Dortmund, Germany
Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters
🇩🇪Berlin, Germany
Uniklinik Essen; Gynäkologie
🇩🇪Essen, Germany
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH
🇩🇪Georgsmarienhütte, Germany
Facharztzentrum Eppendorf, Studien GbR
🇩🇪Hamburg, Germany
Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie
🇩🇪Halle, Germany
St. Elisabeth-Krankenhaus; Brustzentrum
🇩🇪Köln, Germany
Universitätsklinikum Hamburg-Eppendorf; Frauenklinik
🇩🇪Hamburg, Germany
Universitätsklinikum Schleswig-Holstein; Campus Lübeck
🇩🇪Lübeck, Germany
Praxis Köppler, Heymann, Weide, Thomalla; Fä Für Innere Medizin
🇩🇪Koblenz, Germany
Klinikum rechts der Isar der TU München; Klinik und Poliklinik für Frauenheilkunde
🇩🇪München, Germany
MVZ Nordhausen gGmbH, Praxis Dr. Grafe
🇩🇪Nordhausen, Germany
Gemeinschaftspraxis für Hämatologie und Onkologie
🇩🇪Münster, Germany
Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie
🇩🇪Recklinghausen, Germany
Mutterhaus der Borromäerinnen gGmbH, Abteilung Hämatologie-Onkologie
🇩🇪Trier, Germany
IASO General Hospital of Athens
🇬🇷Athens, Greece
Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine
🇬🇷Athens, Greece
Fövárosi Önkormányzat uzsoki utcai Kórház
🇭🇺Budapest, Hungary
Euromedical General Clinic of Thessaloniki; Oncology Department
🇬🇷Thessaloniki, Greece
Grupo Angeles
🇬🇹Guatemala City, Guatemala
University Hospital of Patras Medical Oncology
🇬🇷Patras, Greece
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
🇭🇺Szeged, Hungary
Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly
🇭🇺Budapest, Hungary
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica
🇮🇹Napoli, Campania, Italy
Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica
🇮🇹Milano, Lombardia, Italy
Gunma Prefectural Cancer Center
🇯🇵Gunma, Japan
Fukushima Medical University Hospital
🇯🇵Fukushima, Japan
Aichi Cancer Center Hospital
🇯🇵Aichi, Japan
Hiroshima University Hospital
🇯🇵Hiroshima, Japan
National Hospital Organization Hokkaido Cancer Center
🇯🇵Hokkaido, Japan
Tokai University Hospital
🇯🇵Kanagawa, Japan
Hyogo Medical University Hospital
🇯🇵Hyogo, Japan
Sagara Hospital
🇯🇵Kagoshima, Japan
St. Marianna University Hospital
🇯🇵Kanagawa, Japan
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
Kyoto University Hospital
🇯🇵Kyoto, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Mie University Hospital
🇯🇵Mie, Japan
Tohoku University Hospital
🇯🇵Miyagi, Japan
Naha-nishi Clinic
🇯🇵Okinawa, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Kindai University Hospital
🇯🇵Osaka, Japan
Osaka International Cancer Institute
🇯🇵Osaka, Japan
Saitama Medical University International Medical Center
🇯🇵Saitama, Japan
Shizuoka Cancer Center
🇯🇵Shizuoka, Japan
Saitama Cancer Center
🇯🇵Saitama, Japan
St. Luke's International Hospital
🇯🇵Tokyo, Japan
National Cancer Center Hospital
🇯🇵Tokyo, Japan
Komagome Hospital
🇯🇵Tokyo, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Daugavpils Regional Hospital
🇱🇻Daugavpils, Latvia
Riga East Clinical University Hospital Latvian Oncology Centre
🇱🇻Riga, Latvia
Centro Medico Dalinde
🇲🇽Cdmx, Mexico CITY (federal District), Mexico
Centro Médico Zambrano Hellion
🇲🇽Monterrey, Nuevo LEON, Mexico
Helse Bergen HF Haukeland universitetssjukehus kreftavdelingen poliklinikk
🇳🇴Bergen, Norway
Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
🇵🇱Kraków, Poland
Centro Oncológico de Panamá
🇵🇦Panama, Panama
Centrum Onkologii w Bydgoszczy; Oddzial Kliniczny Onkologii
🇵🇱Bydgoszcz, Poland
Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii
🇵🇱Lublin, Poland
Wojskowy Instytut Medyczny
🇵🇱Warszawa, Poland
Oncomed SRL
🇷🇴Timisoara, Romania
Moscow City Oncology Hospital #62
🇷🇺Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation
Blokhin Cancer Research Center; Combined Treatment
🇷🇺Moskva, Moskovskaja Oblast, Russian Federation
Ivanovo Regional Oncology Dispensary
🇷🇺Ivanovo, Russian Federation
Clinical Oncology Dispensary of Ministry of Health of Tatarstan
🇷🇺Kazan, Russian Federation
National University Hospital
🇸🇬Singapore, Singapore
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
🇷🇺Saint-Petersburg, Russian Federation
National Cancer Centre
🇸🇬Singapore, Singapore
Hospital Universitario Reina Sofia; Servicio de Oncologia
🇪🇸Córdoba, Cordoba, Spain
Hospital del Mar; Servicio de Oncologia
🇪🇸Barcelona, Spain
Hospital Universitario 12 de Octubre; Servicio de Oncologia
🇪🇸Madrid, Spain
Sodersjukhuset; Onkologkliniken
🇸🇪Stockholm, Sweden
Hospital Duran i Reynals; Oncologia
🇪🇸Barcelona, Spain
Hospital Universitario La Paz; Servicio de Oncologia
🇪🇸Madrid, Spain
Instituto Valenciano Oncologia; Oncologia Medica
🇪🇸Valencia, Spain
Akademiska sjukhuset, Onkologkliniken
🇸🇪Uppsala, Sweden
Universitaetsspital Basel; Onkologie
🇨🇭Basel, Switzerland
Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery
🇨🇳Kaohsiung, Taiwan
National Taiwan Uni Hospital; General Surgery
🇨🇳Taipei, Taiwan
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
🇹🇭Bangkok, Thailand
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
🇹🇭Bangkok, Thailand
Songklanagarind Hospital; Department of Oncology
🇹🇭Songkhla, Thailand
Medipol University MF; Oncology Department
🇹🇷Istanbul, Turkey
Cukurova Uni Faculty of Medicine; Medical Oncology
🇹🇷Adana, Turkey
Kyiv City Clinical Oncological Center
🇺🇦Kyiv, Ukraine
Chemotherapy SI Dnipropetrovsk MA of MOHU
🇺🇦Dnipropetrovsk, Ukraine
Hacettepe Uni Medical Faculty Hospital; Oncology Dept
🇹🇷Sihhiye/Ankara, Turkey
Lviv State Oncology Regional Treatment and Diagnostic Centre
🇺🇦Lviv, Ukraine
Guys ST Thomas Hospital
🇬🇧London, United Kingdom
Western General Hospital; Clinical Oncology
🇬🇧Edinburgh, United Kingdom
St Bartholomew's Hospital
🇬🇧London, United Kingdom
Royal Marsden Hospital - London
🇬🇧London, United Kingdom
Christie Hospital Nhs Trust; Medical Oncology
🇬🇧Manchester, United Kingdom
Royal Preston Hosptial
🇬🇧Preston, United Kingdom
Jackson Oncology Associates, PLLC
🇺🇸Jackson, Mississippi, United States
Centre Leon Berard
🇫🇷Lyon, France
Kaiser Permanente - San Marcos
🇺🇸San Marcos, California, United States
Norwalk Hospital
🇺🇸Norwalk, Connecticut, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
ProHEALTH Care Associates LLP
🇺🇸Lake Success, New York, United States
Magee Womens Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
UZ Leuven Gasthuisberg
🇧🇪Leuven, Belgium
Peninsula and South Eastern Haematology and Oncology Group
🇦🇺Frankston, Victoria, Australia
Peter MacCallum Cancer Centre; Medical Oncology
🇦🇺Melbourne, Victoria, Australia
Icon Cancer Foundation
🇦🇺South Brisbane, Queensland, Australia
Clinic of Oncology, University Clinical Center Sarajevo
🇧🇦Sarajevo, Bosnia and Herzegovina
Santa Casa de Misericordia de Salvador
🇧🇷Salvador, BA, Brazil
Hospital de Caridade de Ijui; Oncologia
🇧🇷Ijui, RS, Brazil
Fakultni nemocnice Olomouc; Onkologicka klinika
🇨🇿Olomouc, Czechia
Centro de Cancer Pontificie Universidad Catolica de Chile
🇨🇱Santiago, Chile
Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen
🇩🇪Heidelberg, Germany
Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden
🇩🇪Dresden, Germany
Dres. Helmut Forstbauer, Carsten Ziske und Kollegen; Onkologische Schwerpunktpraxis
🇩🇪Troisdorf, Germany
Universitätsklinik Tübingen; Frauenklinik & Poliklinik
🇩🇪Tübingen, Germany
Univ General Hosp Heraklion; Medical Oncology
🇬🇷Heraklion, Greece
Hiroshima City Hiroshima Citizens Hospital
🇯🇵Hiroshima, Japan
National Hospital Organization Osaka National Hospital
🇯🇵Osaka, Japan
Szpitale Wojewodzkie w Gdyni Sp. z o.o.
🇵🇱Gdynia, Poland
Arkhangelsk Regional Clinical Oncology Dispensary
🇷🇺Arkhangelsk, Arhangelsk, Russian Federation
Main Military Clinical Hospital named after N.N. Burdenko
🇷🇺Moscow, Moskovskaja Oblast, Russian Federation
Hospital Univ Vall d'Hebron; Servicio de Oncologia
🇪🇸Barcelona, Spain
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
🇪🇸Malaga, Spain
Kantonsspital St.Gallen Brustzentrum/Chirurgie; Brustzentrum
🇨🇭St. Gallen, Switzerland
Universitätsspital Zürich
🇨🇭Zürich, Switzerland
Ege Uni Medical Faculty Hospital; Oncology Dept
🇹🇷Izmir, Turkey
Istanbul University Cerrahpasa Medical Faculty; Radiation Oncology Department
🇹🇷Istanbul, Turkey
Velindre Cancer Centre
🇬🇧Cardiff, United Kingdom
Derriford Hospital
🇬🇧Plymouth, United Kingdom
Weston Park Hospital
🇬🇧Sheffield, United Kingdom
Fundación CENIT para la Investigación en Neurociencias
🇦🇷Buenos Aires, Argentina
Emad Ibrahim, Md, Inc
🇺🇸Redlands, California, United States
Nepean Cancer Care Centre
🇦🇺Sydney, New South Wales, Australia
Queen Elizabeth II Health Sciences Centre; Oncology
🇨🇦Halifax, Nova Scotia, Canada
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
🇨🇦Kelowna, British Columbia, Canada
Instituto Estatal de Cancerologia Colima
🇲🇽Colima, Mexico
Consultorio de Medicina Especializada; Dentro de Condominio San Francisco
🇲🇽Mexico City, Mexico
Institute of Oncology Ljubljana
🇸🇮Ljubljana, Slovenia
VETERANS GENERAL HOSPITAL; Department of General Surgery
🇨🇳Taipei, Taiwan
Iem-Fucam
🇲🇽D.f., Mexico
Sørlandet Sykehus Kristiansand
🇳🇴Kristiansand, Norway
Stavanger Universitetssykehus, Helse Stavanger HF
🇳🇴Stavanger, Norway
China Medical University Hospital; Surgery
🇨🇳Taichung, Taiwan
British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre
🇨🇦Vancouver, British Columbia, Canada
Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr
🇵🇱Warszawa, Poland
Kaiser Permanente Of Colorado
🇺🇸Aurora, Colorado, United States
Yale Cancer Center; Medical Oncology
🇺🇸New Haven, Connecticut, United States
Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC
🇺🇸Kansas City, Missouri, United States
Cross Cancer Institute ; Dept of Medical Oncology
🇨🇦Edmonton, Alberta, Canada
Stanford Univ School of Med; Oncology
🇺🇸Stanford, California, United States
Wellmont Bristol Regional Medical Center
🇺🇸Bristol, Tennessee, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States
Hospital Sao Jose
🇧🇷Sao Paulo, SP, Brazil
Queen Mary Hospital; Dept of Medicine
🇭🇰Hong Kong, Hong Kong